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2ABSTRACT
People with schizophrenia and related psychotic disorders show abnormalities in several organ systems in 
addition to the central nervous system (CNS); and this contributes to excess mortality. However, it is unclear how
strong the evidence is for alterations across multiple non-CNS systems at the onset of psychosis, how the 
alterations in non-CNS systems compare to findings in the CNS, or how they relate to symptoms. Here, we 
consider these questions, and suggest potential models to account for findings. 
First, we conduct a systematic meta-review to summarize effect sizes for both CNS (focusing on brain structural, 
neurophysiological, and neurochemical parameters) and non-CNS dysfunction (focusing on immune, 
cardiometabolic, and hypothalamic-pituitary-adrenal (HPA) systems) in first episode psychosis (FEP) to determine 
summary effect sizes for each organ system individually. To achieve this, Pubmed was systematically searched 
from 1990 to May 2017 for meta-analyses focusing on these parameters. Case control data was extracted for 165
studies making up these meta-analyses, comprising a total sample size of 13,440. Random effects meta-analyses 
were re-run and effect size magnitudes calculated for the following: immune parameters (IL-1, sIL2R, IL-6, TNF
, TGF, CRP, and total lymphocyte count), effect size range for immune parameters: g = 0.61-1.62; summary 
effect size for immune alterations: g = 1.19 (95% CI:0.82-1.56); cardiometabolic parameters (fasting glucose, 
glucose following the oral glucose tolerance test, fasting insulin, insulin resistance, triglycerides, total cholesterol, 
and LDL cholesterol), effect size range for cardiometabolic parameters: g = 0.14-0.61, summary effect size for 
cardiometabolic alterations: g = 0.23 (95% CI: 0.15-0.31); HPA parameters (cortisol awakening response and 
prolactin), effect size range for HPA parameters: g = 0.62-0.74; summary effect size for HPA parameters: g = 0.68 
(95% CI: 0.32-1.04); brain structural (total brain, total gray matter, total CSF, ventricular, thalamic, hippocampal, 
and caudate nucleus volumes), effect size range for brain structural alterations: g = 0.26-0.58, summary effect 
size for brain structural alterations: g = 0.40 (95% CI: 0.33-0.47); neurophysiological alterations (auditory P300 
amplitude and duration deviant mismatch negativity), effect size range for neurophysiological alterations: g = 
0.77-0.83, summary effect size for neurophysiological alterations: g = 0.80 (95% CI: 0.64-0.96); neurochemical 
3alterations (N-acetyl aspartate concentrations within frontal lobe, temporal lobe, and thalamus), effect size range 
for neurochemical alterations: 0.35-0.50, summary effect size for neurochemical alterations: g = 0.43  (95% CI: 
0.26-0.60). We then grouped the non-CNS organ systems together to give an effect size for overall non-CNS 
alterations (g = 0.58 (95% CI: 0.44-0.72)) and grouped CNS alterations together to give an effect size for overall 
CNS as well (g = 0.50 (95%CI: 0.44-0.56)). The robustness of data for these non-CNS and CNS parameters was 
assessed using Rosenthal’s fail-safe N, and methodological quality of each meta-analysis assessed using the 
AMSTAR checklist (‘A Measurement Tool to Assess Systematic Reviews’). 
Second, we statistically compare summary effect size for overall CNS and overall non-CNS alterations, as well as 
for each organ system separately. The summary effect sizes for overall non-CNS and overall CNS alterations were 
not significantly different in either medicated (P = 0.28) or antipsychotic naïve (P = 0.83) cohorts. However, the 
summary effect size for immune alterations was significantly greater than that for brain structural (P < 0.001) and 
neurochemical alterations (P < 0.001), and no different from neurophysiological alterations (P = 0.05). The 
summary effect size for HPA alterations was not significantly different from brain structural (P = 0.14), 
neurophysiological (P = 0.54), and neurochemical (P = 0.22) alterations. The summary effect size for 
cardiometabolic alterations was significantly lower than neurochemical (P = 0.04), neurophysiological (P < 0.001) 
and brain structural alterations (P = 0.001). These outcomes remained similar in antipsychotic naïve sensitivity 
analyses. 
Third, we consider how non-CNS alterations compare with CNS alterations in FEP, and how non-CNS alterations 
correlate with psychopathological symptoms. We found some, but limited and inconsistent, evidence that non-
CNS alterations were associated with CNS changes and symptoms. 
In conclusion, our findings indicate that there are robust alterations in non-CNS systems in psychosis, and that 
these are broadly similar in magnitude to a range of CNS alterations. We consider three models that could 
account for these findings and discuss implications for future research and treatment.
4INTRODUCTION
Schizophrenia and related psychotic disorders have a worldwide lifetime prevalence of approximately 1%.
1
They
are highly disabling conditions with economic costs over $60 billion per year in the USA.
2,3
Epidemiological 
studies have established that people with psychotic disorders die 15-20 years earlier than the general population, 
and that 60% or more of this premature mortality relates to non-CNS, predominantly cardiovascular, causes.
4-8
Poor physical health has traditionally been blamed on the secondary effects of the illness, be that a consequence 
of the illness itself (e.g. negative symptoms leading to sedentary lifestyle and poor diet),
9
 or a consequence of 
treatment (e.g. second generation antipsychotic use).
10
 In recent years however, studies in first episode patients 
have shown dysfunction in cardiometabolic,
11-16
 immune,
17-21
 and hypothalamic pituitary adrenal (HPA)
22-25
systems. This suggests that psychotic disorders involve multiple systems at onset. However, it is unclear how 
strong the evidence is for abnormalities across these systems, how alterations compare with CNS abnormalities 
seen in the disorder, or how they relate to symptoms. To address these questions, we perform a meta-review of
the magnitude, consistency and robustness of dysfunction across these systems as assessed using peripheral 
markers, and compare findings with representative CNS abnormalities in psychosis. We then review the potential 
models that could explain the associations, before considering both the research and clinical implications of our 
findings.
METHODS
Systematic meta-review summarizing effect size magnitudes for central nervous system and 
non-central nervous system alterations in first episode psychosis 
Full details of methods employed are documented in Supplementary Information (eAppendix 1). Two systematic 
5reviews of meta-analyses were performed according to Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines
26
 (Supplementary Information, eTable 1). Two reviewers (T.P. and E.D.)
independently searched Pubmed from 1990 to May week 2 2017 for each systematic meta-review. For the meta-
review focussing on non-CNS dysfunction, we focused on meta-analyses of findings in three organ systems 
established as showing dysregulation in schizophrenia: the immune,
27
 cardiometabolic,
28
 and HPA
29
 systems. We 
selected meta-analyses reporting markers of immune, cardiometabolic and HPA system differences between 
patient and control groups, rather than differences in rates of diagnoses of conditions based on pre-defined 
diagnostic criteria
30-33
 (e.g. rates of diagnoses of type 2 diabetes mellitus or hypercholesterolemia). The rationale 
behind this methodology was threefold. Firstly, patients with psychotic illness are less likely to seek medical 
attention and so there is the risk of under-reporting of diagnoses.
34
 Secondly, certain conditions such as glucose 
and lipid dysregulation develop on a continuum and take time for serum/plasma markers to reach threshold for a 
diagnosis. For example, changes in glucose regulation occur 4-7 years prior to diagnosis of type 2 diabetes 
mellitus.
35
Thirdly, physiological alterations that do not meet diagnostic thresholds can, nevertheless, be 
associated with worsened mortality/morbidity outcomes. For example, there is robust evidence that low-grade 
inflammation is an independent risk factor for atherosclerosis and cardiovascular disease.
36
For the meta-review 
focussing on CNS dysfunction, we focused on meta-analyses of parameters previously identified in an expert 
review as key neurobiological alterations seen in schizophrenia,
37
 covering alterations in brain structure, 
neurophysiology, and neurochemistry.  The search was limited to first episode psychosis (FEP) to limit secondary 
effects of illness. 
Patient and control data from the studies referenced in the meta-analyses that our search terms had identified 
were extracted and all meta-analyses repeated. Data were only extracted for those CNS and non-CNS parameters 
where there were significant differences demonstrated between FEP and controls in the original meta-analyses. 
A 2-tailed P < 0.05 was deemed significant. A minimum of 3 studies was required to run a meta-analysis. For non-
CNS parameters, random-effects meta-analyses were performed examining immune (interleukin-1 (IL-1), 
soluble interleukin-2 receptor (sIL-2R), interleukin-6 (IL-6), tumour necrosis factor- (TNF-), transforming 
6growth factor- (TGF-), C-reactive protein (CRP), and total lymphocyte count), cardiometabolic (fasting glucose, 
glucose post-oral glucose tolerance test (OGTT), fasting insulin, insulin resistance (HOMA-IR), total cholesterol, 
low density lipoprotein (LDL) cholesterol, and triglycerides), and HPA parameters (cortisol awakening response 
and prolactin concentrations). For CNS parameters, random-effects meta-analyses were performed examining 
brain structural (total brain volume, total grey matter volume, total CSF volume, right and left hippocampus, right 
and left lateral ventricle, total thalamus, right and left caudate nucleus), neurophysiological (Auditory P300 
amplitude and latency, duration deviant mismatch negativity), and neurochemical parameters (frontal, temporal 
and thalamus N-acetylaspartic acid (NAA) levels). A random effects model was used in all analyses owing to an 
expectation of heterogeneity of data across studies. Standardized mean differences between patient and control 
cohort parameters were used as the effect size, determined using Hedges adjusted g. The 95% CI of the effect 
size was also calculated. A criticism of meta-analysis is that it may be based on a biased sample of studies, 
potentially inflating effect sizes. Thus, for each meta-analysis, Rosenthal’s ‘fail-safe N’
38
 was used to calculate the 
number of additional null  studies (i.e. studies where the effect size is zero) that would be required to increase 
the p value for a given meta-analysis to greater than 0.05. This provides an assessment of how bias could
influence the results of a meta-analysis: the greater the number of estimated studies required for the finding to 
be no longer significant, the less likely the results are secondary to publication or small sample bias and therefore 
the more robust the finding. Methodological quality of each meta-analysis was assessed using the AMSTAR 
checklist (‘A Measurement Tool to Assess Systematic Reviews’) (eAppendix 2). Heterogeneity scores for samples 
within each meta-analysis were also recorded, as assessed using the 
2
 test, Q, or I
2
statistic (tables 1 and 2). 
 As well as individual meta-analyses being run for each parameter as described, 6 separate sub-group meta-
analyses were performed examining data for overall immune, cardiometabolic, HPA, brain structural, 
neurophysiological, and neurochemical systems. Sub-group summary effect size magnitudes were calculated by 
running a combined analysis of all studies assigned to a sub-group (e.g. to calculate the summary effect size 
magnitude for immune alterations, a single analysis was performed that combined IL-1,sIL-2R, IL-6, TNF-, TGF-
,CRP, and total lymphocyte count data sets). If a single study provided results for more than one sub-group 
7parameter (e.g. data for several cytokines from a single study population), then the patient and control numbers 
for that study were divided by the number of parameters contributed to the summary meta-analysis (e.g. if 2 
different cytokines were reported by a single study, then the population number for that study was divided by 2).
Using the same methodology, overall meta-analyses for CNS and non-CNS alterations were calculated. Sensitivity 
analyses for antipsychotic naïve FEP were performed. 
Statistical comparison of effect sizes for central nervous system and non-central nervous 
system alterations in first episode psychosis
After obtaining effect size estimates for each CNS (brain structural, neurophysiological, and neurochemical) and 
non-CNS system (immune, cardiometabolic, and HPA), we next performed bivariate comparisons of each of these
6 effect sizes against one another using a Wald-type test. We determined statistical significance by entering each 
pair of effect size estimates into a fixed effects model (given that the residual heterogeneity had previously been 
accounted for in the initial random effects meta analyses). P < 0.05 was deemed significant. This method was also 
used to compare overall summary CNS and non-CNS effect sizes. Sensitivity analyses were performed restricting 
analyses to antipsychotic naïve cohorts. All statistical tests were conducted using the metafor package
39
 in the R 
statistical programming language.   
RESULTS
For non-CNS dysfunction, of 365 citations retrieved, 15 meta-analyses met inclusion criteria
11-25
 (table 1). For CNS 
dysfunction, of 446 citations retrieved, 13 meta-analyses met inclusion criteria
40-52
 (table 2). Data were extracted 
from a total of 165 case control studies (eAppendix 3). After excluding overlapping samples, the total sample size 
was 13,440 (6806 patients and 6634 controls), with 6817 in the non-CNS sample (3300 patients and 3517 
controls), and 6623 in the CNS sample (3506 patients and 3117 controls). The quality of studies was medium to 
high (AMSTAR scores 6-10, tables 1 and 2).
8Meta-analytic outcomes for central nervous system and non-central nervous system 
alterations in first episode psychosis 
Figure 1A depicts a forest plot for magnitude of immune, cardiometabolic, HPA, brain structural, 
neurophysiological, and neurochemical alterations in first episode psychosis compared with healthy controls, as 
well as overall summary effect sizes for CNS and non-CNS alterations. As per Cohen’s guidelines,
53
 a medium 
overall summary effect size for non-CNS alterations in FEP was observed, (g=0.58 (95% CI: 0.44-0.72). A medium 
overall summary effect size for CNS alterations in FEP was also observed (g=0.50 (95%CI: 0.44-0.56). Similar 
results were observed in antipsychotic naïve sensitivity analyses (effect size for non-CNS alterations: g=0.51 (95% 
CI: 0.34-0.67); effect size for CNS alterations: g=0.48 (95%CI: 0.39-0.58), eFigure 3). 
The immune system
Five meta-analyses examining immune disturbances in FEP were identified.
17-21
Four meta-analyses examined 
inflammatory mediators,
17-20
 and one lymphocyte counts.
21
After allowing for overlapping studies, data were 
extracted for a total sample size of 1343 patients and 1643 controls. FEP is associated with elevated blood 
cytokine levels, specifically IL-1, sIL2R, IL-6, TNF, TGF, CRP, and elevated total lymphocyte counts (effect size 
range: 0.61-1.62) (figure 1A). The summary effect size of immune alterations in FEP is 1.19 (95% CI: 0.82-1.56). 
Fail-safe N calculations demonstrated that between 17 and 1639 additional negative studies would be required 
for these findings to lose significance. Heterogeneity of studies was low to high (I
2
: 0-98%), and study quality 
medium to high (AMSTAR: 6-9). Antipsychotic naïve FEP is associated with elevated blood cytokine levels, 
specifically IL-1, sIL2R, IL-6, and TNF (effect size: 1.00-1.86). The overall effect size for magnitude of immune 
alterations in antipsychotic naïve FEP is 1.46 (95% CI: 0.74-2.18) (eFigure 3).
The cardiometabolic system
Six meta-analyses examining cardiometabolic dysfunction in FEP were identified.
11-16,54
  Three meta-analyses 
focused on glucose and insulin disturbance,
11-13
 two on lipid disturbance,
14,16
 and one on oxidative stress.
15
After 
9allowing for overlapping studies, data were extracted for a total sample size of 1556 patients and 1480 controls. 
All data extracted were for antipsychotic naïve individuals. Antipsychotic naïve FEP is associated with elevated 
fasting glucose, glucose following the oral glucose tolerance test, fasting insulin, and insulin resistance (effect size 
range 0.20-0.61), raised triglycerides (effect size: 0.14), and reduced total cholesterol and LDL cholesterol (effect 
size range: -0.22 - -0.19) (figure 1A). We were unable to extract sufficient data to allow for a meta-analysis of 
oxidative stress parameters in FEP. The summary effect size of cardiometabolic alterations in antipsychotic naïve
FEP is 0.23 (95% CI: 0.15-0.31). Fail-safe N calculations demonstrate that between 26 and 97 additional negative 
studies would be required for findings to lose significance. Heterogeneity was low to high (I
2
: 0-97%), and study 
quality medium to high (AMSTAR: 7-10). 
The hypothalamic-pituitary-adrenal system
Four meta-analyses examining HPA dysregulation in FEP were identified.
22-25
Two meta-analyses reported on 
morning cortisol,
23,24
 one on cortisol awakening response,
22
 and one on prolactin levels.
25
 Prolactin levels were 
included as a marker of HPA axis activation owing to previous evidence that its levels increase in response to 
various stressors, with a direct correlation observed between prolactin levels and both adrenocorticotrophic 
hormone and cortisol levels in healthy controls.
55
  Data were extracted for a total sample size of 401 patients and 
394 controls. The cortisol awakening response is blunted in FEP (effect size: 0.62), and prolactin levels are 
elevated in antipsychotic naïve FEP
25
(effect size: 0.74) (figure 1A). The summary effect size of HPA alterations in 
FEP is 0.68 (95% CI: 0.32-1.04).  Fail-safe N calculations demonstrate that between 75 and 125 negative studies 
would be required for these findings to lose significance. Heterogeneity was low to high (I
2
: 24-83%), and study 
quality high (AMSTAR: 9-10). There were insufficient data to allow for a meta-analysis of cortisol awakening 
response in antipsychotic naïve FEP. 
Central nervous system: brain structural changes
Eight meta-analyses examining brain structure in FEP were identified.
40,42-47,56
 Data were extracted for a total 
sample size of 1937 patients and 1656 controls. FEP is associated with reductions in both total and regional brain 
10
volumes (effect size: 0.26-0.58), and an increase in CSF volume (effect size: 0.34) (figure 1A). The summary effect 
size of brain structural alteration in FEP is 0.40 (95% CI: 0.33-0.47). Fail-safe N calculations demonstrate that 
between 27 and 663 additional negative studies would be required for these findings to lose significance. 
Heterogeneity was low to medium (I
2
: 9-56%), and study quality medium (AMSTAR: 4-7). Antipsychotic naïve FEP 
is also associated with total and regional brain volume reduction (effect size: 0.23-0.87), and an in increase in 
total CSF volume (effect size: 0.32). The summary effect size of brain structural alterations in antipsychotic naïve
FEP is 0.44 (95% CI: 0.34-0.54) (eFigure 3). 
Central nervous system: neurophysiological changes
Four meta-analyses examining neurophysiological changes in FEP were identified.
48-51
Data were extracted for a 
total sample size of 1051 patients and 980 controls. FEP is associated with decreased auditory P300 amplitude 
(effect size: 0.83), and reduced duration-deviant mismatch negativity (effect size: 0.77) (figure 1A).  The summary 
effect size for magnitude of neurophysiological alteration in FEP is 0.80 (95% CI: 0.64-0.96). Fail-safe N 
calculations demonstrate that between 450 and 1100 additional negative studies would be required for these 
findings to lose significance. Sample heterogeneity was medium to high (I
2
: 55-86%), and study quality medium to 
high (AMSTAR: 4-8). Antipsychotic naïve FEP is associated with a reduction in auditory P300 amplitude (effect 
size: 0.86) and latency (effect size: 0.63), as well as a reduction in duration-deviant mismatch negativity (effect 
size: 0.67). The overall effect size for magnitude of neurophysiological alterations in antipsychotic naïve FEP is 
0.70 (95% CI: 0.47-0.94) (eFigure 3). 
Central nervous system: neurochemical changes
One meta-analysis examining brain chemistry in FEP was identified.
52
Data were extracted for a total sample size 
of 518 patients and 481 controls. FEP is associated with decreased levels of N-acetyl aspartate concentrations 
across multiple brain regions (effect size: 0.35 to 0.50) (figure 1A). The overall effect size for magnitude of 
neurochemical alteration in FEP is 0.43 (95% CI: 0.26-0.60). Fail-safe N calculations demonstrate that between 19 
and 359 additional negative studies would be required for these findings to lose significance. Sample 
heterogeneity was low to medium (I
2
: 23-63%), and study quality medium (AMSTAR: 5). Antipsychotic naïve FEP is 
11
associated with a reduction in frontal cortical NAA (ES: 0.34) (eFigure 3).
Statistical comparison of effect sizes for central nervous system and non-central nervous 
system alterations in first episode psychosis 
Overall CNS and non-CNS effect sizes were compared using a Wald-type test.  There was no significant difference 
between the overall effect size of alterations in the CNS compared with the overall effect size of alterations in 
the non-CNS systems examined (P=0.283), and this remained the case when analyses were restricted to studies of 
antipsychotic naïve patients (P=0.825). 
Individual system comparisons
A heat map of respective Wald scores and associated significance values between each of the systems examined 
(immune, cardiometabolic, HPA, brain structural, neurochemical, and neurophysiological) was constructed to 
allow graphical representation of the relative effect size magnitude difference between systems (figure 1B). Wald 
test comparisons of overall immune effect size with CNS effect sizes in FEP demonstrated significantly higher 
effect size magnitudes for immune alterations compared with brain structural (P<0.001) and neurochemical 
(P<0.001) alterations, and no significant difference when compared with neurophysiological alterations 
(P=0.053). For antipsychotic naïve FEP, summary effect size for immune alterations was significantly higher in 
antipsychotic naïve FEP compared with brain structural (P=0.006) and neurochemical alterations (P=0.005), and 
no significant difference when compared with neurophysiological alterations (P=0.05) (eFigure 4). Comparisons 
of the summary effect size for cardiometabolic alterations with those for CNS alterations in antipsychotic naïve 
FEP demonstrated significantly reduced effect size magnitudes for cardiometabolic alterations compared with 
brain structural (P=0.001), neurochemical (P=0.04), and neurophysiological alterations (P<0.001). Comparisons of 
summary effect size of HPA with those for CNS alterations in FEP demonstrated no significant difference when 
compared with brain structural (P= 0.14), neurochemical (P = 0.217), and neurophysiological (P = 0.541) 
alterations.
12
Correlations between non-central nervous system parameters and central nervous system
parameters
In view of evidence of both CNS and non-CNS alterations in FEP, we examined evidence for associations between 
these parameters. Only a limited number of observational studies have investigated relationships between CNS 
and non-CNS measures in FEP. Studies in broader psychotic illness including schizophrenia present data that is 
conflicting, which may reflect the heterogeneity of the population studied, but also the multi-faceted roles of the 
metabolic, immune, and endocrine parameters we have examined. For example, IL-6 has both 
neurodegenerative
57
 and neuroprotective properties.
58
Thus, conflicting outcomes with regards correlations 
between pro-inflammatory cytokines and brain structural alterations might be expected. Indeed, in 
schizophrenia, hippocampal volumes correlate directly with the pro-inflammatory cytokine interleukin-18,
59
while pro-inflammatory IL-1 titres correlate indirectly with Broca’s area volume in a ‘pro-inflammatory’ 
subgroup of patients.
60
Thus, we have evidence of elevated pro-inflammatory cytokines being differentially 
associated with regional brain volume alterations: further studies are required to clarify regional brain structural 
alterations in the context of systemic inflammation in FEP. In terms of HPA axis alterations and influence on 
regional brain structure, although one study has failed to demonstrate a relationship between cortisol levels and 
hippocampal volume in FEP,
61
 Mondelli and colleagues have reported an inverse correlation between blood
cortisol levels and hippocampal volumes,
62
 and the degree of left-sided hippocampal volume reduction has been 
associated with a blunted cortisol awakening response in FEP.
63
Beyond brain structural alterations, in 
schizophrenia, diffusion tensor imaging has demonstrated that peripheral IL-6 levels inversely correlate with 
measures of fractional anisotropy in the forceps major, inferior longitudinal fasciculus (ILF), and inferior fronto-
occipital fasciculus (IFOF), a relationship not demonstrated in healthy controls. In both the ILF and IFOF, IL-6 
levels correlate directly with radial diffusivity measures. CRP levels in schizophrenia also show an inverse
correlation with fractional anisotropy within the forceps major.
64
 Thus, in psychosis, selected neural pathways 
may be differentially susceptible to systemic immune alterations, although replication of these findings is 
required. We were unable to find any studies in FEP exploring correlations between CNS parameters and 
13
cardiometabolic disturbances. In individuals with type 2 diabetes who do not have a psychotic disorder, insulin 
resistance is associated with hippocampal atrophy and memory impairment.
65
 Since cognitive impairment is a 
key feature of psychotic illness, and we have demonstrated that antipsychotic naïve FEP is associated with both
insulin resistance and reduced hippocampal volumes, future structural imaging studies combined with metabolic 
assays are required to clarify if a correlation between impaired glucose homeostasis and hippocampal structural 
alterations also exists in FEP.  
Correlations between non-CNS parameters and symptom severity
Although the evidence presented indicates that cardiometabolic, immune, and HPA alterations are present in 
early psychosis, this does not indicate whether these abnormalities are linked to the clinical expression of the 
disorder. As such we also examined evidence of a ‘biological gradient’ between these markers and symptom 
measures. In antipsychotic naïve FEP, positive symptom severity, as assessed using the Positive and Negative 
Syndrome Scale (PANSS), correlates directly with fasting glucose levels
66
 and insulin resistance,
67
 indicating more 
severe symptoms are associated with more marked glucoregulatory disturbance. As part of a meta-analysis 
examining CRP titres in schizophrenia performed by Fernandes and colleagues,
68
meta-regression of effect size 
for CRP changes on PANSS positive scores demonstrated that the greater the severity of positive symptoms, the 
greater the increase in CRP (r=0.12; 95% CI 0.03-0,23; P=0.013). Broader evidence for a biological gradient 
between symptom severity and inflammatory cytokines in psychosis is however inconsistent and contradictory. 
For example, in antipsychotic naïve FEP, levels of the anti-inflammatory cytokine IL-10 inversely correlate with 
PANSS negative scores
69
 indicating this anti-inflammatory marker is associated with less severe symptoms,
however PANSS positive scores in FEP have been observed to inversely correlate with pro-inflammatory IL-6.
70
Studies in broader psychotic illness have demonstrated that IL-6 levels correlate directly with total 
psychopathology,
71,72
however others have failed to demonstrate an association.
73-75
No significant correlations 
have been reported between TNF-, IL-1, IL-12, and TGF- levels with symptomatology in FEP.
76-79
Correlations 
14
between HPA axis alterations and symptom severity in FEP are similarly inconsistent and contradictory. For 
example, although cortisol levels have been observed to directly correlate with symptom severity,
80-82
 there have
been negative studies,
83-85
 and inverse correlations with illness severity  reported.
86
Varied outcomes may be a 
consequence of heterogeneity of patient populations and parameter measurement techniques between studies. 
Future projects may benefit from recruitment of a more homogenous group of participants, either by applying
more stringent diagnostic inclusion criteria (e.g. focussing on individuals with predominant negative or positive 
symptoms, as demonstrated by Kirkpatrick and colleagues who defined differences in glucose tolerance between 
deficit and nondeficit schizophrenia)
87
 or by stratifying patients based on a pre-defined physiological parameter 
(e.g. a ‘pro-inflammatory’ group based on cytokine titres).
60
DISCUSSION
The evidence analysed in this review, compiled from 165 case control studies and an overall sample size of 
13,440 subjects, indicates that there are a range of significant non-CNS as well as CNS alterations in patients with 
first episode psychosis (summarised in figure 2A), and that the overall magnitudes of alteration for CNS and non-
CNS alterations are not significantly different. Fail-safe N calculations, which provide a surrogate marker of how 
robust these findings are, demonstrate that large numbers of null studies would need to be added to these meta-
analyses for both CNS and non-CNS outcomes to lose statistical significance (fail-safe N ranges: immune 17 to 
1639; HPA 75 to 125; cardiometabolic 26 to 97; brain structural 27 to 663; neurophysiological 450 to 1100; 
neurochemical 19 to 359). Although our review of observational studies in psychosis suggests that there may be a 
link between certain non-CNS and CNS alterations as well as some non-CNS parameters and symptom severity,
the number of these correlative studies is small and the results are inconsistent, making definitive inferences 
difficult.
Strengths and limitations
15
The major strength of this meta-review is its focus on FEP and antipsychotic naïve data. Thus, where possible the 
confounding effects of illness chronicity and treatment were limited. There are of course limitations to studies 
examining physical dysfunction in FEP (see limitations box). It is important to recognise that the FEP population is 
inevitably diagnostically heterogenous. To investigate the degree of heterogeneity we extracted the diagnoses of 
patients from each study where reported (see eAppendix4). This shows that the overall proportion of FEP 
patients included in our analyses who had a diagnosis of schizophrenia was 74% in the non-CNS group and 84% in 
the CNS group. Whilst some of the patients without a diagnosis of schizophrenia will go on to develop 
schizophrenia, it still important to recognise that some will never develop schizophrenia and, consequently, our 
findings should not be taken as being specific to schizophrenia. Whilst the difference in the proportion with 
schizophrenia between groups is modest, we cannot exclude that this has moderated the effect sizes.  Thus, we 
recommend future FEP studies include follow-up to determine diagnoses, and report findings separately by 
diagnosis to enable this to be tested.  The specificity of findings is also low, with other serious mental illnesses 
showing similar physiological dysfunction.
88,89
 However, it should be recognised that many of the same factors 
apply to CNS alterations, and reverse causality is possible, with lifestyle factors potentially impacting both CNS 
and non-CNS measures. For example smoking,
90
 stress,
91
 drug,
92
 and alcohol
93
 abuse are associated with gray 
matter volume loss. Despite our focus on early psychosis, studies often fail to report or examine the impact of
duration of untreated psychosis. As such it remains possible that non-CNS changes are secondary to emerging 
psychotic symptoms, e.g. due to resultant poor lifestyle habits, social isolation and stress.
94,95
Moreover, 
inconsistencies in studies investigating a ‘biological gradient’ between CNS and non-CNS alterations, and non-CNS 
alterations with symptom severity, limit arguments regarding non-CNS alterations contributing to pathological 
causality in psychosis as per Bradford Hill’s guidelines.
96
Although meta-analysis as a methodology is a powerful 
tool to summarise research knowledge in a field, it has limitations.
97
 These limitations relate to the reliability of a 
meta-analysis’ outcome being dependent on the quality of the data meta-analysed, the size of the samples 
included, the potential for type 1 error owing to publication bias towards ‘positive’ results, and the heterogeneity 
of study populations included. However, our quality assessment of meta-analyses selected for this review was 
reassuring, with only medium-high quality analyses included. Although heterogeneity of studies documented by
16
these meta-analyses varied, our meta-analyses used a random effects model which is robust to heterogeneity.
The fail-safe N approach has limitations.
98
 For example, the formula assumes that the mean effect of unpublished
null studies is zero, whereas studies may also have negative effect sizes, thereby requiring fewer studies to nullify 
the mean effect.  However, the fail-safe N was applied across organ systems, thus, assuming there is similar 
publication bias across CNS and non-CNS research fields in psychosis, we can be confident that the fail-safe N is a 
reasonable quantitative measure by which the relative strength of the evidence supporting alterations in CNS and 
non-CNS parameters can be assessed. Indeed, fail-safe N calculations suggest outcomes for certain CNS and non-
CNS parameters are more robust than others (figure 1A). Of the 15 comparative Wald analyses between CNS and 
non-CNS alterations in FEP, only 4 contrasts changed significance (based on <0.05) when moving from 
medicated to antipsychotic naïve sensitivity analyses. There was no difference overall between CNS and non-CNS 
effect size magnitudes in both medicated and antipsychotic naïve cohorts. This suggests that antipsychotic 
treatment does not significantly moderate effect sizes documented, providing further evidence that CNS and non-
CNS alterations co-occur in FEP.
The putative nature of the relationship between central nervous system and non-central 
nervous system abnormalities in first episode psychosis
Figures 2B, 2C, and 2D illustrate three putative models that could explain our findings of both non-CNS and CNS 
abnormalities in FEP. Model 1 (figure 2B) shows how a risk factor inducing non-CNS dysfunction may lead to 
development of non-CNS disorders as well as impacting CNS function leading to psychosis. An example is that of 
paraneoplastic-induced anti-N-methyl-D-aspartate (NMDA)-receptor encephalitis which is associated with 
psychosis. Resection of the causative tumor is associated with resolution of psychotic experiences.
99
 More 
broadly, immune dysregulation could be responsible for co-development of psychosis and cardiometabolic 
disease. Pre-clinical studies demonstrate that peripheral inflammation can induce neuro-inflammation,
100
 which 
could potentially contribute to the pathogenesis of psychosis.
101
 There is also evidence of inflammatory cytokines 
modulating dopaminergic and glutamatergic neurotransmission.
102,103
 As dysfunction in these neurotransmitters 
is implicated in the development of psychosis,
104
 this could link cytokine alterations to development of psychosis. 
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As chronic inflammation is associated with accelerated atherosclerotic plaque formation, insulin resistance, and 
increased cardiovascular risk,
36
 elevated cytokines in psychosis could also be playing a role in the increased risk of 
cardiovascular disease in this population. Altered lipid turnover both peripherally and centrally may also be a 
consequence of an inflammatory process in FEP. Total and LDL cholesterol are reduced in antipsychotic naïve FEP 
compared with healthy controls, a finding that is maintained in body mass index (BMI) sensitivity analyses.
14,16
 It 
has been hypothesised that the pro-inflammatory state of FEP is responsible for a ‘paradoxical’ reduction in 
cholesterol via a similar mechanism seen in inflammatory arthritides.
16
 Whether a similar mechanism modulates 
CNS lipid metabolism in schizophrenia and thus plays a role in disease pathogenesis through resultant synaptic 
dysfunction remains unclear. Such a mechanism would fit with model 1. In contrast, model 2 (figure 2C) shows 
how a risk factor can induce CNS dysfunction resulting in psychotic symptoms which then trigger non-CNS 
dysfunction. An example is that the stress of psychosis could lead to HPA axis activation. Supporting this, 
psychological stress increases cortisol levels.
105
 Cortisol excess is associated with hypertension, obesity, insulin 
resistance, dyslipidemia and cardiovascular disease.
106
 Thus, hypercortisolemia associated with psychosis may be 
contributing to cardiometabolic disease. It should however be recognized that, in addition to causing non-CNS 
dysfunction, stress may also contribute to the development of psychosis,
107
 suggesting a model whereby an 
exposure contributes jointly to CNS and non-CNS dysfunction.  Finally, model 3 (figure 2D) proposes that a 
common risk factor has independent, and parallel effects that result in the separate development of psychosis 
and non-CNS dysfunction.  For example, population-based cohort studies have demonstrated that 
cardiometabolic disease
108
 and psychosis share risk factors, including low-birth weight,
109
 pre-term birth
110,111
 and 
maternal malnutrition.
112,113
Nutritional deficiencies in utero may result in neurodevelopmental changes 
increasing vulnerability to psychosis.
114
 Nutritional deficiencies may also result in epigenetic changes relating to 
metabolic function, leading to metabolic alterations and ultimately diabetes.
115
 Similarly, there may be shared 
genetic risk between psychosis and non-CNS disturbances. Genome-wide association studies have demonstrated 
pleiotropic enrichment between genes conferring risk for schizophrenia and non-CNS alterations, including 
immune and metabolic processes.
116,117
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Critique and comparison of the models
The models discussed above are intended to summarise the main potential relationships that exist between CNS 
and non-CNS alterations in psychosis, and it should be recognised that there is evidence for and against each 
model. The relative strengths and weakness of the 3 models proposed are summarised in Supplementary 
Information (eBox 1). Model 1 is supported by cases where a non-CNS disorder clearly predates psychosis, which 
resolves when the non-CNS disorder is treated, such as the example of NMDA auto-antibodies leading to 
psychosis discussed above, but these cases are rare.
99
 Moreover, population-based cohort studies have observed 
that elevated levels of serum CRP
118
 and IL-6
119
 in childhood are associated with increased risk of psychotic 
experience and schizophrenia in adulthood. Furthermore, the North American Prodrome Longitudinal Study 
(NAPLS)
120
 has provided evidence that hypercortisolemia, inflammation, and elevated oxidative stress in 
individuals already deemed to be at risk for developing psychosis are risk factors for transition to FEP. However, 
many associations between non-CNS dysfunction and psychosis have not shown evidence of causation to date. To 
demonstrate causality, non-CNS dysfunction needs to be addressed prior to the onset of psychosis, for example in 
the prodrome, and show that the development of psychosis is prevented. In addition, although model 1 explains 
rare cases of psychosis, it is unlikely to account for typical cases of schizophrenia where CNS alterations are 
thought to occur early in neurodevelopment,
107
 unless non-CNS alterations also occur very early in development. 
Model 2, where non-CNS dysfunction emerges as a consequence of psychosis, is supported by meta-analytic 
evidence that resolution of acute psychosis is associated with normalization of previously elevated cytokines (IL-1
, IL-6, and TGF-).
19
 Also, there is only limited evidence for alterations of certain non-CNS parameters in the 
prodrome (e.g. glucose and lipid disturbances), suggesting their later development may be a consequence of 
psychosis or its treatment. However, as described in support of model 1, several non-CNS alterations have been 
demonstrated in the prodrome. In addition, the observed reduction in levels of cytokines in association with the 
resolution of an acute psychotic episode could be part of the therapeutic action of treatment (supportive of 
model 1 rather than 2). Model 3, where a shared risk factor plays a role in development of psychosis and non-
CNS alterations through divergent mechanisms is supported by the lack of consistent relationships between a 
number of CNS and non-CNS alterations. Also, the heterogeneity in both non-CNS and CNS findings between 
19
patients could suggest divergent mechanisms underlie them.
121
 However, we have identified certain correlations,
e.g. between glucose dysregulation,
66
 insulin resistance,
67
 and PANSS positive scores in FEP, that point towards 
these non-CNS alterations being linked with the clinical expression of psychosis, consistent with, although not 
proving, a common pathoetiological mechanism. Moreover, there is a paucity of studies testing relationships 
between non-CNS and CNS alterations in psychosis, limiting any conclusions regarding common causality.  
Overall, there is both supportive and contradictory evidence for all 3 models, and aspects of each model that 
remain to be fully tested. The contradictory evidence suggests that one model is unlikely to account for all cases 
of psychosis. Moreover, whilst the models provide an overarching framework, the specific mechanisms that 
might link risk factors, CNS and non-CNS alterations need to be investigated. Further work is clearly needed, 
particularly to investigate the causal nature of relationships, and how common they are to patients in general.
Does the involvement of multiple systems in first episode psychosis indicate that psychosis is 
a multi-system disorder?
Conceptually, multisystem disorders can be categorized into two groups:
122
1) conditions where multiple organ 
systems are pervasively affected with no single predominant organ involved (e.g. inborn errors of metabolism);
2) conditions where one organ system is predominantly affected, but where other organs may concurrently be 
involved (e.g. rheumatoid arthritis). Since psychosis is by definition a description of psychological phenomena, it 
would be hard to argue that psychosis meets the first definition. However, consistent with the second definition, 
the evidence reviewed above suggests that early in psychosis dysfunction is present across multiple organ 
systems. Given the large effect sizes and number of negative studies required for many of these to become no 
longer significant, these findings appear robust, at least as robust as for many of the brain structural/functional 
alterations seen in psychosis. Moreover, we found that there is some, albeit limited, evidence that non-CNS 
measures are linked to symptoms and CNS changes in FEP. This could be taken as suggesting that psychosis, and 
by extension schizophrenia, should be considered a multi-system disorder. However, the International 
Classification of Disease-11 2010 Steering Group discussion paper on multisystem diseases,
122
 defined these as 
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‘diseases that regularly manifest without involvement of a common single system and with concomitant major 
involvement of several systems’, and, on this basis, a disorder such as rheumatoid arthritis would not be
considered multi-system because, whilst it affects multiple systems, its predominant manifestation is 
musculoskeletal. By the same token, given that psychosis by definition is a disorder of thought and behavior, it is 
clear that CNS dysfunction bears the most direct relationship with the clinical expression of the disorder. This
argues against psychosis being a multi-system disorder. However, this argument is inherently circular because 
psychotic disorders are diagnosed solely on the basis of mental symptoms. Here, whilst the evidence reviewed 
above goes some way to showing the magnitude of non-CNS effects is similar, in some cases larger, than CNS 
effects, what is currently lacking is robust evidence that the changes in non-CNS systems have commensurate 
clinical impacts, for example on functioning, prognosis or mortality. Evidence is also needed on the nature of the 
relationship between CNS and non-CNS changes: if non-CNS changes are found to be due to a common 
pathoetiology or risk factor (model 3) or lead to CNS changes (model 1), this could support psychosis being a 
multi-system disorder, whilst finding that non-CNS alterations are secondary to mental symptoms (model 2)
would not.  A consequence of this would potentially be that diagnostic and prognostic assessment might 
incorporate assessment of non-CNS organ dysfunction in addition to assessment of thought and behavior. For 
example, if the pathophysiology of FEP includes a hypercortisolemic, pro-inflammatory state, then a biomarker 
‘fingerprint’ of antipsychotic naïve FEP could conceivably include evidence of HPA axis dysregulation (e.g. blunted 
cortisol awakening response) with raised peripheral cytokines (e.g. IL-6) as well as relevant measures of CNS 
function.
Implications and future directions
Further research is required to elucidate whether non-CNS dysfunction is a cause or a consequence of psychosis.
Longitudinal studies of non-CNS parameters starting in people at clinical high risk for psychosis and continuing 
through development of psychosis is a potential approach, and has the advantage of including a control group 
exposed to the same risk factors (those individuals who do not develop psychosis), as well as the research 
advantage that a number will develop other mental disorders. This group could help address another key 
21
question, which is the degree to which non-CNS alterations are specific to psychosis or are a common feature of a 
number of mental disorders, potentially consistent with a model whereby the stress of mental illness leads to 
changes in other systems
123
(model 2). Other key areas that our review has highlighted as requiring further work 
are the degree to which alterations in non-CNS systems are linked to psychotic symptoms, and other clinical 
outcomes, and whether common pathoetiological mechanisms underlie both CNS and non-CNS alterations. 
In terms of clinical practice, the majority of excess mortality seen in schizophrenia is due to non-CNS causes,
predominantly cardiovascular disease,
8
 and life-expectancy in schizophrenia has failed to improve relative to the 
general population over recent decades.
1
Our findings of cardiometabolic, inflammatory and HPA axis alterations 
in FEP suggest that processes underlying excess mortality are present early in schizophrenia and other psychotic 
disorders. One implication for clinicians is to routinely consider these systems in the assessment of psychotic 
disorders. Studies are needed to determine if addressing non-CNS alterations early reduces development of 
physical co-morbidity, and ultimately reduces mortality in psychotic disorders (see summary box).
CONCLUSIONS
Abnormalities in multiple organ systems in addition to the CNS are seen at onset of psychotic disorders with 
similar magnitudes to those seen in the CNS. Whilst the causal relationship between non-CNS and CNS alterations 
remains to be determined, this evidence indicates that psychosis involves multiple systems from illness onset, 
although is not sufficient to define it as a multi-system disorder. 
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Limitations
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First episode psychosis samples are heterogenous, including patients with a number of different 1.
psychotic disorders. This limits extrapolation of these findings to particular disorders, although 
the majority of patients included met criteria for schizophrenia.
Included studies often fail to report duration of untreated psychosis, thus impact of emerging 2.
psychosis on physical health is not quantified. 
Other serious mental illnesses e.g. depression show similar physiological alterations, therefore 3.
these findings may not be specific to psychosis. 
According to fail-safe N calculations, certain findings (e.g. immune and neurophysiological 4.
outcomes) are more robust than others. Outcomes of certain systems (e.g. HPA axis and CNS
neurochemistry) are limited by small sample sizes.
Meta-analysis as a methodology has limitations when small sample sizes are used, if study 5.
populations are heterogenous, if studies are of poor quality, and when publication bias exists.
Inconsistencies in demonstrating a ‘biological gradient’ between CNS and non-CNS alterations, 6.
and non-CNS alterations with symptom severity, limit arguments regarding the non-CNS 
associations observed contributing to pathological causality.
Although aimed to be representative, the CNS and non-CNS systems reviewed were not 7.
exhaustive, and other non-CNS organ systems implicated in psychotic illness, e.g. the 
gastrointestinal system were not discussed. Similarly, indices of CNS function e.g. cognitive
function were not discussed.  
Summary of findings and outstanding questions
Non-CNS abnormalities occur with similar effect sizes as CNS abnormalities in FEP. 1.
Non-CNS abnormalities may be a cause or consequence of CNS dysfunction in psychosis or an 2.
epiphenomenon. Clarification of the causal relationship is required.
The predominance of mental symptoms in psychosis currently argues against re-conceptualising 3.
psychotic disorder as a multi-system disorder, but this is partly a function of the mental basis of 
the diagnosis.
 Studies are needed to determine if addressing non-CNS dysfunction from illness onset may 4.
contribute to reducing schizophrenia’s excess mortality rates. 
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Table 1: Meta-analyses examining cardiometabolic, hypothalamic-pituitary-adrenal (HPA) axis, and 
immune alterations in first episode psychosis that met inclusion criteria. HC: healthy control; OGTT: oral 
glucose tolerance test; FG: fasting glucose; IR: insulin resistance; TC: total cholesterol; LDL: low density lipoprotein; 
HDL: high density lipoprotein; TG: triglyceride; TAS: total antioxidant status; RBC: red blood cell; CAT: catalase; GSH-
Px: glutathione peroxidase; SOD: superoxide dismutase; MDA: malondialdehyde; TBARS: thiobarbituric acid reactive 
substances; IL: interleukin; TNF-: tumour necrosis factor-; IFN-: interferon-; TGF-: transforming growth factor-
; CAR: cortisol awakening response; AMSTAR: ‘A Measurement Tool to Assess Systematic Reviews’. 
Meta-
analysis
Objective No. Of 
studies
Study 
Range
Anti-
psychotic 
status
Patient/
HC No.
Non-CNS 
parameter
Effect size Hetero-
geneity (I
2
)
AMSTAR
Pillinger et 
al., 201711
Cardiometaboli
c profile 
16 2003-
2016
Minimal (<2 
weeks, 
antipsychotic 
naïve sub-
group)
731/614 Fasting glucose ↑ 0.30
P = 0.002
58-82% 10/11
Glucose post-OGTT ↑ 0.61
P = 0.007  
Fasting insulin ↑ 0.47 
P = 0.04
Insulin resistance ↑ 0.44
P < 0.001
HbA1c ↔ -0.08 
P > 0.05
Perry et al., 
201612
Cardiometaboli
c profile
12 2003-
2015
Minimal (<1 
week)
564/573 Fasting glucose; ↔ 0.06
P > 0.05  
0-94% 10/11
Glucose post-OGTT ↑ 0.82
P < 0.0001
Insulin resistance ↑ 0.26
P < 0.0001
Greenhalgh 
et al., 201613
Cardiometaboli
c profile
19 2003-
2016
Minimal (<1 
week)
911/870 Fasting glucose ↑ 0.21
P < 0.001
55-83% 9/11
Glucose post-OGTT ↑ 0.58
P < 0.001
Fasting insulin ↑ 0.28
P < 0.001 
Insulin resistance ↑ 0.30
P < 0.001
Misiak et al., 
201714
Cardiometaboli
c profile
19 2000-
2016
Antipsychotic 
naïve
866/937 Total cholesterol ↓ -0.16
P = 0.003
0-74% 11/11
HDL cholesterol ↓ -0.27
P = 0.018
LDL cholesterol ↓ -0.13
P = 0.034
Triglycerides ↑ 0.22
P < 0.00
Pillinger et 
al., 201754
Cardiometaboli
c profile
20 2003-
2016
Minimal (<2 
weeks)
1167/1184 Total cholesterol ↓ -0.19
P = 0.005
29-77% 10/11
HDL cholesterol ↔-0.22
P = 0.065
LDL cholesterol ↓ -0.22
P = 0.001
Triglycerides ↑ 0.14
P < 0.05
Leptin ↔ 0.05
P =0.779
Flatow et al., 
201315
Cardiometaboli
c profile
18 1996-
2012
Not naïve 535/615 Plasma TAS ↓ -1.42
P < 0.01
No I2 values. 2
P value range 
<0.01 – 0.91
7/11
Serum TAS ↓ -1.12
P < 0.01 
RBC CAT ↓ -0.48
P < 0.01
RBC GSH-Px ↔ 0.18
P = 0.26
RBC SOD ↓ -0.79
P < 0.01
Plasma SOD ↑ 0.45
P < 0.01  
Plasma MDA ↑ 2.36
P < 0.01
Plasma TBARS ↑ 0.88
P < 0.01
Plasma nitrite ↓ -0.70
P < 0.01
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Plasma uric acid ↓ -0.55
P < 0.01
Upthegrove 
et al., 201417
Immune profile 23 1990-
2012
Antipsychotic 
naïve
570/683 IL-1 ↑ 1.17
P < 0.0001
DNA 6/11
IL-2 ↔ -0.20
P = 0.772
sIL-2R ↑ 1.34
P < 0.0001
IL-4 ↑ 0.20
P = 0.861
IL-6 ↑ 2.21
P = 0.013
TNF- ↑ 0.94
P < 0.0001
IFN- ↔ 0.24
P = 0.760
Goldsmith et 
al., 201618
Immune profile 24 1989-
2014
Not naïve  1393/1497 IL-1 ↑ 1.25
P < 0.01
0-97% 9/11
IL-1RA ↑ 0.29
P < 0.01
IL-2 ↔ 0.08
P = 0.48
sIL-2R ↑ 1.04
P < 0.01
IL-4 ↓ -0.63
P < 0.01
IL-6 ↑ 1.16
P < 0.01
IL-8 ↑ 1.75
P < 0.01
IL-10 ↑ 0.18
P = 0.01
IL-12 ↑ 0.26
P = 0.02
IL-17 ↔ 0.00
P = 0.99
IL-18 ↔ 0.08
P = 0.28
TNF- ↑ 0.31
P < 0.01
TGF- ↑ 0.58
P < 0.01
IFN- ↑ 0.23
P < 0.01
Miller et al., 
201119
Immune profile 13 1989-
2010
Antipsychotic 
naïve/free (sub-
group)
481/633 IL-1 ↑ 0.60
P < 0.001
60-98% 8/11
IL-2 ↔ -0.09
P = 0.44
sIL-2R ↑ 1.03
P < 0.001
IL-6 ↑ 1.40
P < 0.001
IL-12 ↑ 0.98
P < 0.001
TNF- ↑ 0.81
P < 0.001
TGF- ↑ 0.48
P < 0.001
IFN- ↑ 0.57
P = 0.001
Fernandes et 
al., 201620
Immune profile Not naive 348/360 C-reactive protein CRP: 0.63
P = 0.038
87% 9/11
Miller et al., 
201321
Immune profile 5 1990-
2008
Antipsychotic 
naïve
125/323 Total lymphocytes ↑ 0.77
P < 0.01
0-57% 7/11
CD3 lymphocytes ↑ 0.72
P < 0.01
CD4 lymphocytes ↑ 0.86
P<0.01
CD8 lymphocytes ↔ 0.44
P = 0.10
B lymphocytes ↔ 0.30
P = 0.13
Berger et al., 
201622
HPA axis profile 6 2008-
2015
Not naïve  251/216 Cortisol awakening 
response
↓-0.54
P < 0.001
24% 10/11
Chaumette et 
al., 201623
HPA axis profile 6 2007-
2014
Not naïve  215/226 Basal cortisol ↔ -0.15
P = 0.56  
77% 10/11
Girshkin et 
al., 201424
HPA axis profile 10 1996-
2013
Not naïve  285/282 Basal cortisol ↔ -0.10
P = 0.644
83% 9/11
Gonzalez-
Blanco et al., 
201625
HPA axis profile 8 1990-
2014
Minimal (<1 
week)
Male
141/191
Prolactin ↑ 1.02
P < 0.001
81% 10/11
6 Female
67/116
Prolactin ↑ 0.43
P < 0.01
66% 9/11
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Table 2: Meta-analyses examining CNS alterations in first episode psychosis that met inclusion criteria.
NAA: N-acetyl aspartate; MMN: mismatch negativity; WM: white matter; PLIC: posterior limb of the internal 
capsule; CSF: cerebrospinal fluid; L: left; R: right. AMSTAR: ‘A Measurement Tool to Assess Systematic Reviews’.   
Meta-
analysis
Objective No. of
studies
Study 
range
Anti-
psychotic 
status
Patient/
HC No.
CNS parameter Effect size Hetero-
geneity (I
2
/Q)
AMSTAR
Bora et al., 
201156
Structural 13 2003-
2010
Not naïve 415/459 Superior temporal gyrus ↓ -0.29 
P<0.000005
Not 
specified
7/11
415/459 Right dorsal anterior 
cingulate
↓ -0.24
P = 0.0002
4 2006-
2010
127/120 Fractional anisotropy 
reduction: L temporal WM
↓ -0.40
P = 0.00004
127/120 Fractional anisotropy 
reduction: R PLIC
↓ -0.34
P = 0.0003
Adriano et 
al., 201240
Structural 13 1998-
2010
Not naïve 388/562 Right Hippocampal volume ↓ -0.56
P <0.00001
16% 7/11
388/562 Left Hippocampal volume ↓ -0.60 
P < 0.00001
56%
Adriano et 
al., 201042
Structural 15 1999-
2009
Not naïve 173/211 Right Thalamus volume ↓ -0.45
P < 0.0001
0% 6/11
173/211 Left Thalamus Volume ↓ -0.48
P < 0.0001
0%
Haijma et 
al., 201343
Structural 15 1998-
2011
Antipsychotic 
naïve
364/490 Total brain volume ↓ -0.21 
P = 0.003
0% 5/11
10 238/292 Total gray matter ↓ -0.36 
P=0.000066
0%
7 182/286 Total CSF 0.31
P = 0.011
30%
8 194/251 Hippocampal volume ↓ -0.43
P = 0.0000076
0%
7 152/260 Thalamus volume ↓ -0.68
P = 0.00083
67%
10 299/422 Caudate nucleus ↓ -0.38
P=0.00000095
0%
Vita and de 
Peri, 200744
Structural 7 1990-
2006
Not naïve 290/355 Right hippocampal volume ↓ -0.36
P <0.05
Not 
specified
4/11
Left hippocampal volume ↓ -0.57
P <0.05
de Peri et 
al., 201245
Structural 21 1991-
2011
Not naïve 686/772 Total brain volume ↓ -0.26 
P < 0.001
Q = 34.21
P = 0.02
6/11
12 412/438 Total gray matter ↓ -0.36
P < 0.001
Q = 13.23
P = 0.27
8 308/319 Lateral ventricles (total) ↑ 0.38
P < 0.001
Q = 3.62
P = 0.82
12 396/429 Right lateral ventricle ↑ 0.40
P < 0.001
Q = 7.57
P = 0.75
12 396/429 Left lateral ventricle ↑ 0.49
P < 0.001
Q = 11.09
P = 0.37
Vita et al., 
200646
Structural 11 1991-
2003
Not naïve 340/422 Total brain volume ↓ -0.24
P = 0.002
Not 
specified
5/11
8 241/206 Right lateral ventricle ↑ 0.47
P < 0.0001
8 241/206 Left lateral ventricle ↑ 0.61
P < 0.0001
4 114/102 Total lateral ventricle ↑ 0.32 
P = 0.022 
6 204/162 Third ventricle ↑ 0.59
P < 0.0001
4 121/101 Right temporal lobe ↔ -0.07
P = 0.617
4 121/101 Left temporal lobe ↔ -0.15
P = 0.258
6 187/268 Right hippocampus ↓ -0.47
P < 0.0001
6 187/268 Left hippocampus ↓ -0.66
P < 0.0001
Fusar-Poli et 
al., 201247
Structural 8 Not 
specified
Antipsychotic 
naïve
206/202 Total gray matter ↓ -0.83
P < 0.001
9% 5/11
206/202 Superior temporal gyrus gray 
matter volume
↓ -0.56
P < 0.00005
Erickson et 
al., 201648
Neuro-
physiologic 
13 1999-
2015
Not naïve 331/393 Mismatch negativity 
amplitude
↑0.42
P < 0.05
Not 
specified
5/11
Qiu et al., 
201449
Neuro-
physiologic
17 1998-
2009
Not naïve 569/747 P300 amplitude ↓ -0.83
P = 0.00001
55% 8/11
16 506/747 P300 latency ↑ 0.48
P = 0.005
86%
Chen et al., 
201450
Neuro-
functional
4 2003-
2014
Antipsychotic 
naïve
105/214 P300 latency -0.13
P = 0.31
‘not 
significant’
4/11
P300 amplitude ↔0.48
P = 0.05
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Haigh et al., 
201751
Neuro-
physiologic
9 2002-
2013
Not naïve 242/395 Pitch deviant MMN ↔ -0.04
P > 0.05
Not 
specified
4/11
10 360/531 Duration deviant MMN ↓ -0.47
P < 0.05
Brugger et 
al., 201152
Neuro-
chemical 
19 1997-
2009
Not naïve 376/428 Frontal NAA levels ↓ -0.45
P < 0.0001
49% 5/11
11 232/189 Temporal NAA levels ↓ -0.53
P = 0.0025
63%
5 102/88 Thalamus NAA levels ↓ -0.40
P = 0.0203
23%
6 125/91 Basal Ganglia NAA levels ↔ -0.09
P = 0.599
24%
Figure Legends
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Figure 1: An overview and comparison of CNS and non-CNS alterations in first episode psychosis. Figure 1A: 
Forest plot for magnitude of immune, cardiometabolic, HPA, brain structural, neurophysiological, and 
neurochemical alterations in first episode psychosis compared with healthy controls. Each line represents a 
summary effect size for a meta-analysis in one parameter: squares represent the summary effect size for that 
parameter, with the horizontal line running through each square illustrating the width of the overall 95% CI. Blue 
diamonds represent summary effect sizes for immune, cardiometabolic, HPA, structural, neurophysiological, and 
neurochemical systems: the middle of each diamond represents the summary effect size, and the width of the 
diamond depicts the width of the overall 95% CI. Red diamonds represent summary effect sizes and 
accompanying 95% CI for non-CNS and CNS effect sizes. ES: effect size; CNS: central nervous system; FEP: first 
episode psychosis; HPA: hypothalamic pituitary adrenal axis; IL1: interleukin-1; sIL2-R: soluble interleukin-2 
receptor; IL6: interleukin-6; TGF:  transforming growth factor-; CRP: C-reactive protein; NAA: N-acetylaspartic 
acid; N: number. Figure 1B: Heat map comparing relative magnitude of effect sizes (ES) for immune, 
hypothalamic pituitary adrenal (HPA) axis, cardiometabolic, brain structural, neurophysiological, and 
neurochemical alterations in first episode psychosis (FEP). The map is read from left to right, comparing 
parameters on the y axis with parameters on the x axis. A negative Wald score (blue squares) demonstrates that 
the parameter ES on the y axis is numerically lower compared with the intersecting parameter ES on the x axis. A 
positive Wald score (red squares) demonstrates that the parameter ES on the y axis is numerically higher than 
the intersecting parameter ES on the x axis. Numbers within the squares are the P values that accompany the 
Wald score e.g. structural abnormalities show significantly smaller patient-control differences compared to 
immune abnormalities, and significantly greater differences compared to cardiometabolic abnormalities.
Figure 2: A summary of non-CNS alterations in first episode psychosis, and a consideration of potential 
pathoetiology. Figure 2A: First episode psychosis shows alterations in multiple systems in addition to the 
central nervous system. OGTT: oral glucose tolerance test; HDL: high density lipoprotein; LDL: low density 
lipoprotein. Figures 2B-D: Models of the relationship between psychosis and non-CNS dysfunction. Figure 2B:
Model 1: A risk factor induces non-CNS dysfunction, which may consequently impact CNS function to increase the 
risk of psychosis. Figure 2C: Model 2: A risk factor induces CNS dysfunction and thence psychotic symptoms, 
which may consequently trigger non-CNS dysfunction. Figure 2D: Model 3: A shared risk factor may result in the 
development of psychosis and non-CNS dysfunction through independent mechanisms. CNS: central nervous 
system.
Type of file: figure
Label: 1
Filename: figure_1.jpg
Page 1 of 1
22/02/2018file:///C:/Adlib%20Express/Work/20180222T084624.593/%7B7360B3DA-F1...

Type of file: figure
Label: 2
Filename: figure_2.jpg
Page 1 of 1
22/02/2018file:///C:/Adlib%20Express/Work/20180222T084624.593/%7B0CED3B8E-A...

Europe PMC plus has received the file 'supp_info_1.docx' as supplementary data. The file 
will not appear in this PDF Receipt, but it will be linked to the web version of your 
manuscript. 
Page 1 of 1
22/02/2018file:///C:/Adlib%20Express/Work/20180222T084624.593/%7B840F8A6E-5C...
Europe PMC plus has received the file 'supp_info_2.docx' as supplementary data. The file 
will not appear in this PDF Receipt, but it will be linked to the web version of your 
manuscript. 
Page 1 of 1
22/02/2018file:///C:/Adlib%20Express/Work/20180222T084624.593/%7B01B4A7FD-24...
